MCM
SRDX

Moore Capital Management’s Surmodics SRDX Stock Holding History

Moore Capital Management’s Portfolio SRDX Stock Details SRDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,000
Closed -$1.05M – 551
2024
Q2 		$1.05M Buy
+25,000
New +$853K 0.02% 315

Other funds holding SRDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moore Capital Management's SRDX Position: Q3 2025 in Review

Moore Capital Management sold out of Surmodics (SRDX) in Q3 2025, closing a stake of 10,000 shares — an estimated $297K sold.

Moore Capital Management first reported a position in SRDX in Q1 2025 and held it in 2 quarters. The position peaked at $611K in Q1 2025. 146 funds tracked by Wall St. Rank hold SRDX as of Q3 2025.

  • Moore Capital Management reported no remaining Surmodics position as of Q3 2025 after selling out during the quarter.
  • Moore Capital Management sold 10,000 Surmodics shares in Q3 2025, an estimated $297K.
  • Moore Capital Management first reported a position in Surmodics in Q1 2025 and held it in 2 quarters.
  • Moore Capital Management's Surmodics position peaked at $611K in Q1 2025.
  • 146 funds tracked by Wall St. Rank held Surmodics as of Q3 2025.

Based on Moore Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.